When should bladder cancer prompt evaluation for Lynch syndrome? An evidence-informed clinical framework
- 1Department of Urology, Rambam Health Care Campus
Abstract
Lynch syndrome (LS) is an established cause of urothelial cancer, yet hereditary evaluation remains far better defined for upper tract urothelial carcinoma than for bladder cancer. The clinically relevant question is not whether bladder cancer belongs to the LS spectrum, but when a bladder cancer diagnosis should prompt evaluation for previously unrecognized LS. This mini-review examines the clinical and molecular findings that may justify hereditary assessment in patients presenting with bladder cancer and proposes an evidence-informed framework for their interpretation. The strongest signals include a known familial LS variant, a personal or family history of LS-associated malignancy, and tumor evidence of mismatch repair deficiency, microsatellite instability, or a pathogenic MMR alteration. Previous or synchronous upper tract disease and younger age may increase suspicion, whereas tumor grade alone is insufficiently specific. Tumor testing should guide, but not replace, germline evaluation, and negative tumor findings do not fully exclude hereditary disease when clinical suspicion remains high. Confirmation of LS has clear implications for lifelong cancer prevention and cascade testing, while its effect on bladder cancer treatment and urologic surveillance remains uncertain. Prospective bladder-specific studies are needed to validate testing strategies and define clinical actionability.
Related
- Risk stratification of pediatric chest pain: red flags, diagnostic yield, and an evidence-informed clinical framework
- Real-world evaluation of a multilingual agentic retrieval-augmented clinical AI framework for evidence-grounded medical decision support
- Choosing Between Anti-TROP2 ADCs in Advanced Breast Cancer Without Head-to-Head Evidence: A Practical Evidence-Informed Decision Framework Endorsed by the Polish Society of Clinical Oncology.
- Wild Boar-Related Injuries in Wilderness Environments: Field-Oriented Management Principles and Evidence-Informed Clinical Recommendations
- Phenotype-informed selection of microbiota-directed interventions in irritable bowel syndrome: current evidence and limitations
BibTeX
@article{fazaa2026when,
title = {{When should bladder cancer prompt evaluation for Lynch syndrome? An evidence-informed clinical framework}},
author = {Nicola Fazaa and Maya Gofer and Etan Eigner and Melissa Atallah and Yuval Shafran and Gilad Amiel and Azik Hoffman},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.2015634},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.2015634/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - When should bladder cancer prompt evaluation for Lynch syndrome? An evidence-informed clinical framework
AU - Nicola Fazaa
AU - Maya Gofer
AU - Etan Eigner
AU - Melissa Atallah
AU - Yuval Shafran
AU - Gilad Amiel
AU - Azik Hoffman
PY - 2026
DA - 2026/10/28
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.2015634
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.2015634/full
AB - Lynch syndrome (LS) is an established cause of urothelial cancer, yet hereditary evaluation remains far better defined for upper tract urothelial carcinoma than for bladder cancer. The clinically relevant question is not whether bladder cancer belongs to the LS spectrum, but when a bladder cancer diagnosis should prompt evaluation for previously unrecognized LS. This mini-review examines the clinical and molecular findings that may justify hereditary assessment in patients presenting with bladder cancer and proposes an evidence-informed framework for their interpretation. The strongest signals include a known familial LS variant, a personal or family history of LS-associated malignancy, and tumor evidence of mismatch repair deficiency, microsatellite instability, or a pathogenic MMR alteration. Previous or synchronous upper tract disease and younger age may increase suspicion, whereas tumor grade alone is insufficiently specific. Tumor testing should guide, but not replace, germline evaluation, and negative tumor findings do not fully exclude hereditary disease when clinical suspicion remains high. Confirmation of LS has clear implications for lifelong cancer prevention and cascade testing, while its effect on bladder cancer treatment and urologic surveillance remains uncertain. Prospective bladder-specific studies are needed to validate testing strategies and define clinical actionability.
SN - 2234-943X
ER -